Therapeutic advances in medical oncology · 2026
Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kawaguchi Yasunori, Hayashi Kohei, Shimokawa Mototsugu, Otsuka Taiga, Nakazawa Junichi, Shimokawa Hozumi, Shinohara Yudai, Koga Futa, Oza Noriko, Oda Hisanobu, Takeshita Shigeyuki, Arima Shiho, Arita Shuji, Nishikawa Kazuo, Otsu Satoshi, Taguchi Hiroki, Jikuya Kenichi, Sakai Tatsunori, Ueda Yujiro, Sakae Takahiro, Araki Norimasa, Sawase Hironori, Ide Yasushi, Kawahira Machiko, Nio Kenta, Shirakawa Tsuyoshi, Mizuta Toshihiko, Mitsugi Kenji
Аннотация
BACKGROUND: Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard second- or later-line regimen for unresectable or recurrent pancreatic cancer (urPC). However, validated prognostic biomarkers are lacking.
OBJECTIVES: In this study, we aimed to identify clinical predictors of progression-free survival (PFS) in patients receiving NFF and to develop a nomogram for early prediction of therapeutic efficacy.
DESIGN: This was a pre-planned analysis of a prospective, multicenter observational study conducted across 17 hospitals in Japan.
METHODS: We enrolled 150 patients with urPC who received NFF between 2021 and 2023. Prognostic factors independently associated with PFS were identified using multivariable Cox proportional hazards regression analysis. Based on these factors, we constructed a nomogram to estimate the probabilities of 2-, 4-, and 6-month PFS. Finally, we performed risk stratification according to total nomogram scores and validated this model using an independent retrospective cohort.
RESULTS: The median overall survival was 7.8 months, and the median PFS was 3.7 months. Multivariable analysis identified a longer duration of previous chemotherapy (hazard ratio (HR), 0.52; 95% confidence interval (CI), 0.38-0.71; p < 0.01) as a favorable prognostic factor; third-line treatment (vs second-line; HR, 1.67; 95% CI, 1.04-2.67, p = 0.03) and higher C-reactive protein/albumin ratio (CAR; HR, 1.14; 95% CI, 1.01-1.29, p = 0.04) were associated with unfavorable PFS. In risk stratification, median PFS in the low-, moderate-, and high-risk groups was 5.9 months (reference), 3.9 months (HR, 1.78; 95% CI, 1.16-2.71; p < 0.01), and 2.2 months (HR, 2.30; 95% CI, 1.51-3.50; p < 0.01), respectively. Significant risk stratification was also confirmed in an independent retrospective cohort.
CONCLUSION: The duration of previous chemotherapy, treatment line, and the CAR are useful predictors of PFS in patients with urPC receiving NFF. The proposed nomogram and risk stratification system may facilitate individualized treatment planning and support clinical decision-making.
OBJECTIVES: In this study, we aimed to identify clinical predictors of progression-free survival (PFS) in patients receiving NFF and to develop a nomogram for early prediction of therapeutic efficacy.
DESIGN: This was a pre-planned analysis of a prospective, multicenter observational study conducted across 17 hospitals in Japan.
METHODS: We enrolled 150 patients with urPC who received NFF between 2021 and 2023. Prognostic factors independently associated with PFS were identified using multivariable Cox proportional hazards regression analysis. Based on these factors, we constructed a nomogram to estimate the probabilities of 2-, 4-, and 6-month PFS. Finally, we performed risk stratification according to total nomogram scores and validated this model using an independent retrospective cohort.
RESULTS: The median overall survival was 7.8 months, and the median PFS was 3.7 months. Multivariable analysis identified a longer duration of previous chemotherapy (hazard ratio (HR), 0.52; 95% confidence interval (CI), 0.38-0.71; p < 0.01) as a favorable prognostic factor; third-line treatment (vs second-line; HR, 1.67; 95% CI, 1.04-2.67, p = 0.03) and higher C-reactive protein/albumin ratio (CAR; HR, 1.14; 95% CI, 1.01-1.29, p = 0.04) were associated with unfavorable PFS. In risk stratification, median PFS in the low-, moderate-, and high-risk groups was 5.9 months (reference), 3.9 months (HR, 1.78; 95% CI, 1.16-2.71; p < 0.01), and 2.2 months (HR, 2.30; 95% CI, 1.51-3.50; p < 0.01), respectively. Significant risk stratification was also confirmed in an independent retrospective cohort.
CONCLUSION: The duration of previous chemotherapy, treatment line, and the CAR are useful predictors of PFS in patients with urPC receiving NFF. The proposed nomogram and risk stratification system may facilitate individualized treatment planning and support clinical decision-making.